BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9198249)

  • 21. Thrombolytic treatment of portal thrombosis.
    Malkowski P; Pawlak J; Michalowicz B; Szczerban J; Wroblewski T; Leowska E; Krawczyk M
    Hepatogastroenterology; 2003; 50(54):2098-100. PubMed ID: 14696472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update in thrombolytic therapy.
    Hacke W; Ringleb P; Stingele R
    Rev Neurol (Paris); 1999; 155(9):662-5. PubMed ID: 10528345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical therapy of acute myocardial infarction: Part I. Role of thrombolytic and antithrombotic therapy.
    Jafri SM; Walters BL; Borzak S
    J Intensive Care Med; 1995; 10(2):54-63. PubMed ID: 10172420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Deep venous thromboses--established treatment procedures and new trends].
    Seifried E
    Z Kardiol; 1993; 82 Suppl 2():49-59. PubMed ID: 8328209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Myocardial infarction and thromboembolism during pregnancy].
    Härtel D; Sorges E; Carlsson J; Römer V; Tebbe U
    Herz; 2003 May; 28(3):175-84. PubMed ID: 12756475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of reperfusion and coronary reocclusion on the variability of heart rate in patients with acute myocardial infarction].
    Pizzi C; Costa GM; Borghi A; Premuda G; Tondini C; Magri G; Cordioli E; Bugiardini R
    Cardiologia; 1999 Feb; 44(2):181-6. PubMed ID: 10208055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant tissue plasminogen activator.
    Bell SG
    Neonatal Netw; 1996 Sep; 15(6):13-8. PubMed ID: 8932068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of aspirin with thrombolytic therapy in acute myocardial infarction.
    Hennekens CH
    Chest; 1990 Apr; 97(4 Suppl):151S-155S. PubMed ID: 2108852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New approaches in plasminogen activator therapy.
    Bode C; Gulba D; Huber K; Runge MS
    Ann Hematol; 1996; 73 Suppl 1():S1-7. PubMed ID: 8853111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1992 Mar; 19(3):678-80. PubMed ID: 1538027
    [No Abstract]   [Full Text] [Related]  

  • 31. Limiting systemic plasminogenolysis reduces the bleeding potential for tissue-type plasminogen activators but not for streptokinase.
    Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Wu DT; Refino CJ; Keyt BA; Bennett WF
    Thromb Haemost; 1996 Jun; 75(6):915-20. PubMed ID: 8822586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The identification of the best thrombolytic. Reflections on a problem without resolution].
    Betriu A
    Rev Esp Cardiol; 1993 Apr; 46(4):242-5. PubMed ID: 8469809
    [No Abstract]   [Full Text] [Related]  

  • 33. Thrombolysis after acute myocardial infarction: are Canadian physicians up to the challenge?
    Williams WL
    CMAJ; 1997 Feb; 156(4):509-11. PubMed ID: 9054820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolytic therapy in acute MI. Weighing the risks and benefits.
    Ro KG; Anderson HV
    Postgrad Med; 1990 Dec; 88(8):79-80, 83-6, 89-90 passim. PubMed ID: 2123035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
    Nedaeinia R; Faraji H; Javanmard SH; Ferns GA; Ghayour-Mobarhan M; Goli M; Mashkani B; Nedaeinia M; Haghighi MHH; Ranjbar M
    Mol Biol Rep; 2020 Jan; 47(1):819-841. PubMed ID: 31677034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.
    Absar S; Gupta N; Nahar K; Ahsan F
    J Thromb Haemost; 2015 Sep; 13(9):1545-56. PubMed ID: 26074048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrin-selective thrombolytic therapy for acute myocardial infarction.
    Collen D
    Circulation; 1996 Mar; 93(5):857-65. PubMed ID: 8598075
    [No Abstract]   [Full Text] [Related]  

  • 38. Does intravenous heparin or time-to-treatment/reperfusion explain differences between GUSTO and ISIS-3 results?
    Anderson JL; Karagounis LA
    Am J Cardiol; 1994 Nov; 74(10):1057-60. PubMed ID: 7977047
    [No Abstract]   [Full Text] [Related]  

  • 39. Thrombolytic therapy.
    Baker WF
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):291-314. PubMed ID: 12516680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reperfusion therapy for stroke.
    Dunbabin D
    Aust N Z J Med; 1999 Jun; 29(3):462-6. PubMed ID: 10868520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.